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The vast majority of the natural compounds that have been previously described 
as inhibitors of angiogenesis have been isolated from plants and terrestrial 
microorganisms, mainly due to their higher availability and because their therapeutic 
effects had been previously known in folk traditional medicines. However, increasing 
attention is being paid to the development of marine-derived antiangiogenic agents, 
probably fuelled by the increase in the number of marine-derived anticancer drugs which 
are being successfully used for cancer therapy. Marine organisms, adapted to survive in 
extreme environments by developing chemical means of defence, produce interesting 
and singular pharmacological lead compounds, derived from the large diversity of 
marine habitats and environmental conditions.  
Among the many different types of marine organisms used as a source for drug 
discovery, sponges represent one of the most promising sources of leads in the 
research of new cancer drugs. Some angiogenesis inhibitors isolated from marine 
sponges have been described by us and others.   
Aeroplysinin-1, a brominated metabolite extracted from the marine sponge 
Aplysina aerophoba, has been characterized by our group as a potent antiangiogenic 
compound in vitro and in vivo. Aeroplysinin-1 induces apoptosis in endothelial cells by a 
mechanism which involves activation of the BH3-only pro-apoptotic protein Bad, 
cytochrome c release and activation of caspases 2, 3, 8 and 9, what indicates a relevant 
role of the mitochondria in the apoptogenic activity of this compound. Recent results 
suggest that aeroplysinin-1 could also be a novel potential anti-inflammatory compound. 
These results open new ways to the potential pharmacological action of aeroplysinin-1 
not only on angiogenesis and cancer, but also on atherosclerosis and inflammation-
dependent diseases. 
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